128,840 Shares in Kenvue Inc. $KVUE Purchased by Commerce Bank

Commerce Bank bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, Holdings Channel reports. The fund bought 128,840 shares of the company’s stock, valued at approximately $2,462,000.

Several other institutional investors and hedge funds also recently bought and sold shares of KVUE. BlackRock Inc. purchased a new stake in shares of Kenvue in the 2nd quarter valued at approximately $2,882,279,000. Norges Bank purchased a new stake in shares of Kenvue during the 4th quarter valued at approximately $756,862,000. Independent Franchise Partners LLP raised its position in shares of Kenvue by 56.3% during the 4th quarter. Independent Franchise Partners LLP now owns 48,146,476 shares of the company’s stock valued at $830,527,000 after buying an additional 17,343,785 shares during the period. Sculptor Capital LP lifted its holdings in Kenvue by 1,023.5% in the fourth quarter. Sculptor Capital LP now owns 12,886,328 shares of the company’s stock valued at $222,289,000 after acquiring an additional 11,739,328 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in Kenvue in the second quarter valued at approximately $192,080,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Shares of KVUE stock opened at $19.41 on Tuesday. The firm’s 50 day moving average price is $19.08 and its 200-day moving average price is $18.21. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. Kenvue Inc. has a one year low of $14.02 and a one year high of $21.63. The firm has a market cap of $37.27 billion, a P/E ratio of 22.30, a P/E/G ratio of 1.36 and a beta of 0.47.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.31 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The company had revenue of $3.96 billion for the quarter, compared to analysts’ expectations of $3.97 billion. During the same period in the previous year, the business posted $0.29 EPS. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Stockholders of record on Wednesday, August 12th will be given a dividend of $0.21 per share. This is an increase from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a dividend yield of 4.3%. The ex-dividend date is Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is 96.55%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of several recent analyst reports. Barclays raised their target price on Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. UBS Group decreased their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Finally, Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and an average price target of $19.27.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.